Business1 outlet
Roche's Second-Quarter Sales Held Back by Blockbuster Eye Drug
Roche's second-quarter sales were disappointing due to slower-than-expected recovery of its blockbuster eye drug Vabysmo. The pharmaceutical company is now relying on new drug launches to drive future growth. Investors are concerned about the underperformance of this key revenue driver.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending